Specialty Pharmacy

Phase 3 data show combination therapy demonstrates clinical benefit as first-line treatment.

A look at last week's top stories in the world of pharmacy.

Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,100.

New analysis examines the role of the HIV/AIDS epidemic in cancer survival rates among adolescents and young adults.

Coinfection with HIV and tuberculosis may affect drug-related adverse events, hospital readmissions, and treatment duration.

Top news of the day from across the health care landscape.

Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

The approval marks the first new antiviral flu treatment with a novel mechanism of action backed by the agency in nearly 20 years.

Study compares 2-year survival between patients with metastatic non-small cell lung cancer treated at academic and community centers.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

Top news of the day from across the health care landscape.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

Top news of the day from across the health care landscape.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

Top news of the day from across the health care landscape.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses the challenges that consolidation brings to the pharmacy industry and how specialty pharmacies can face those challenges.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

The updated label changes include information regarding use of rituximab as a follow up treatment in adults with 2 rare forms of vasculitis.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.